Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients
Michalis Liontos, Evangelos Terpos, Elena Kunadis, Flora Zagouri, Αlexandros Briasoulis, Efi Skafida, Oraianthi Fiste, Christos Markellos, Αngeliki Andrikopoulou, Sentiljana Gumeni, Maria Kaparelou, Konstantinos Koutsoukos, Maria Gavriatopoulou, Efstathios Kastritis, Ioannis P. Trougakos, Meletios Α. Dimopoulos
Topics & Concepts
MedicineProstate cancerEnzalutamideVaccinationImmunosuppressionImmunologyImmune systemOncologyCancerDiseaseImmunotherapyAndrogen deprivation therapyInternal medicineAndrogen receptorSARS-CoV-2 and COVID-19 ResearchCOVID-19 and healthcare impactsCancer Immunotherapy and Biomarkers